SEC Form 4 · accession 0001979825-26-000004
Candel Therapeutics, Inc. · CADL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicoletta Loggia
Director
Period of report
Jun 23, 2026
Accepted (ET)
Jun 24, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001841387
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.08 | Jun 23, 2026 | A | 32,000 | A | — | Jun 23, 2036 | Common Stock | 32,000 | 32,000 | D |
Explanation of responses
- F1This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.